Menu

Javascript is not activated in your browser. This website needs javascript activated to work properly.
You are here

B cells linked to effective cancer immunotherapy

Cancer patients responded better to immunotherapy and had a better prognosis if their melanoma tumours contained specific clusters of B cells, according to new research from Lund University in Sweden. The study is published in Nature.
B cells linked to effective cancer immunotherapyCancer patients responded better to immunotherapy and had a better prognosis if their melanoma tumours contained specific clusters of B cells, according to new research from Lund University in Sweden. The study is published in Nature.

 Göran Jönsson)Immunofluorescence analysis of a melanoma tumor showing that B cells in B cell clusters express CXCR5, a marker for tertiary lymphoid structures. (Source: Göran Jönsson) 

Immunotherapy strengthens the immune system so that it can fight cancer more effectively. One type of immunotherapy is checkpoint therapy, that targets the checkpoints that exist to prevent the immune system from becoming too active. However, releasing these brakes on the immune system is necessary to fight certain types of cancer, something that can be done with antibodies.

But far from all patients are being helped by the treatment, and intensive research is underway to understand who benefits the most from checkpoint therapy, and how it can be made even more effective. A great deal of focus so far has been on the immune cells called T cells.

The new study sheds light on the role of another immune cell in immunotherapy: B cells. Researchers at Lund University, together with several other international research groups, have shown that clusters of B cells in melanoma tumors, so-called tertiary lymphoid structures, are linked to the prognosis.

“By studying tissue samples from 177 melanoma patients, we have been able to see that when these B-cell structures were present in the tumour, the patient had a better prognosis and responded better to immunotherapy”, says Göran Jönsson, the professor at Lund University who led the study.


It has previously been known that these structures are sometimes found in tumours, but it is only now that they have been linked to prognosis and treatment response. In the same issue, Nature has published two other research articles that involve the same B-cell structures, albeit in other tumours - soft tissue sarcoma and kidney cancer – where there was also an association with improved response to immunotherapy.

The results of the Lund study confirm that it is not only the T-cells that are important, but that the B-cells also play a role in the immune response against cancer cells.


“Now we want to continue with prospective studies and investigate whether it is possible to stimulate the immune system to form these structures in tumours, and thus improve the effect of immunotherapy”, concludes Ana Carneiro, chief physician at Skåne University Hospital and associate professor at Lund University, who also participated in the study.

Funders of the study include: The Swedish Cancer Society, Swedish Research Council, Berta Kamprad Foundation, Gustav V Jubilee Fund, Mats Paulsson Foundation, Stefan Paulsson Foundation, Danish Cancer Society, Aase och Einar Danielsens Fund, EU Horizon 2020 Marie Curie grant, Region Skåne.

Publication: Tertiary lymphoid structures improve immunotherapy and survival in melanoma

Contact:
Göran B Jönsson
goran_b [dot] jonsson [at] med [dot] lu [dot] se
+46 46 222 14 44

 

Link to original article published 29 Janauary 2020

 Tove Smeds)Göran Jönsson and Ana Carneiro (Photo: Tove Smeds)

Latest news

3 February 2020

Researchers believe that sugar and obesity can make cancer cells more difficult to kill

Researchers believe that sugar and obesity can make cancer cells more difficult to kill
3 February 2020

Major study gives most comprehensive map of breast cancer risk

Major study gives most comprehensive map of breast cancer risk
3 February 2020

B cells linked to effective cancer immunotherapy

B cells linked to effective cancer immunotherapy
7 January 2020

Prestigious ERC grant for innovative immunotherapy research

Prestigious ERC grant for innovative immunotherapy research
12 December 2019

Tailored Therapy for Chronic Myeloid Leukaemia

Tailored Therapy for Chronic Myeloid Leukaemia

LUCC - Lund University Cancer Centre
Lund University
Box 117, 221 00, Lund, Sweden
Telephone +46 (0) 46 222 0000 (switchboard)